Here is the design of a clinical trial:

Official Title: Feasibility Assessment of the Prophylactic Use of AneuFix at the Time of EVAR Implantation

Included conditions:
- Abdominal Aortic Aneurysm
- Endoleak

Study Armgroups:
- {'label': 'Intervention', 'type': 'EXPERIMENTAL', 'description': 'Device: ANEUFIX', 'interventionNames': ['Device: Prophylactic sac filling with AneuFix']}

Interventions:
- {'type': 'DEVICE', 'name': 'Prophylactic sac filling with AneuFix', 'description': 'ANEUFIX is administered by injection into the AAA via transferal access at the time of EVAR placement using imaging techniques to guide the place of injection.', 'armGroupLabels': ['Intervention']}

Primary Outcomes:
- {'measure': 'Technical Success', 'description': 'Technical Success as demonstrated by the feasibility to fill the AAA sac after EVAR during the same procedure, and by the rate of (all) endoleaks after EVAR followed by the AneuFix procedure', 'timeFrame': '24 hours'}
- {'measure': 'Clinical Success rate', 'description': 'Clinical Success as demonstrated by the occurrence of type II endoleaks at 6 months after EVAR, and aneurysmal sac growth at 6 months after EVAR', 'timeFrame': '6 months'}
- {'measure': 'Clinical Success rate', 'description': 'Clinical Success as demonstrated by the occurrence of type II endoleaks at 12 months after EVAR, and aneurysmal sac growth at 12 months after EVAR', 'timeFrame': '12 months'}

Please estimate the sample size based on the assumption: 
Not explicitly stated in the provided paragraph.
Sample size determination
          First, a pilot study will be conducted with five patients. After DSMB approval, this sample size will be raised to 25 patients by treating another 20 patients. A sample size of 25 has been calculated adequate and sufficient to assess the goals of the study with an independent statistician and instructed by the CE-notified body.